Stopped up for nearly a decade, the pipeline for hepatitis C virus (HCV) is flowing with hope these days as several biotechs advance new candidates that could make treatment easier to stomach.
WASHINGTON – Whether it's funding the "doc fix" or finding potential savings, Medicare's Part D prescription drug program is a popular fix-it target these days.
You think the drug shortage is a devil now Just wait around a few years ’Cause you ain’t seen nothin’ yet. When that biosimilar pathway begins to flash Those big green dollar signs, You’ll know, you’ll know, you’ll know, you just ain’t seen nothin’ yet. Those biosimilars will turn your heart away from the old drugs of yesterday. You’ll think you have it comin’, and you’ll want it that way. You’ll say big profits are good profits, so you’ll take what you can get. B-B-B-Baby, you ain’t seen n-n-n-nothin’ yet. Patients will go to the doctor, and he’ll tell them...
WASHINGTON – Voicing a sense of urgency, FDA Commissioner Margaret Hamburg unveiled a blueprint Wednesday aimed at making the agency a part of the solution, rather than the problem, in promoting innovation in the biotech industry.
WASHINGTON – Although the deadline has come and gone, biopharma is still in the dark about the regulations intended to shed light on how potential conflicts of interest are to be publicly reported.
WASHINGTON – The National Center for Advancing Translational Sciences (NCATS) didn't make the cut in a draft House subcommittee fiscal 2012 appropriations bill for the National Institutes of Health (NIH).
For industry observers who think biosimilars won't stand much of a chance against long-time market dominators in the U.S., Hospira Inc. has one word: Europe.
WASHINGTON – Hoping to avoid future "flash crashes" like the one that played havoc with the markets May 6, 2010, the SEC is proposing changes to the circuit breaker rules it adopted nearly 25 years ago.
WASHINGTON – With unexpected drug shortages becoming the norm, the FDA needs to reallocate its resources to better handle the crisis and improve how, when and what it communicates about those shortages, a group of stakeholders told the agency.
